abrdn plc Acquires 148,522 Shares of Catalent, Inc. (NYSE:CTLT)

abrdn plc lifted its holdings in Catalent, Inc. (NYSE:CTLT) by 338.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 192,443 shares of the company’s stock after acquiring an additional 148,522 shares during the quarter. abrdn plc owned 0.11% of Catalent worth $8,646,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in CTLT. Gladius Capital Management LP bought a new stake in shares of Catalent in the 3rd quarter worth approximately $28,000. Exchange Traded Concepts LLC purchased a new position in shares of Catalent in the third quarter worth $31,000. Cary Street Partners Investment Advisory LLC increased its stake in shares of Catalent by 1,162.3% in the third quarter. Cary Street Partners Investment Advisory LLC now owns 770 shares of the company’s stock worth $35,000 after buying an additional 709 shares during the period. Rakuten Securities Inc. purchased a new position in shares of Catalent in the fourth quarter worth $46,000. Finally, Federated Hermes Inc. purchased a new position in shares of Catalent in the fourth quarter worth $46,000.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $63.50 target price on shares of Catalent in a research note on Tuesday, February 20th. UBS Group reaffirmed a “neutral” rating and issued a $63.50 target price (up from $58.00) on shares of Catalent in a research note on Tuesday, February 6th. Stephens reissued an “equal weight” rating and set a $63.50 price objective on shares of Catalent in a research report on Thursday, April 4th. Barclays upped their price objective on shares of Catalent from $45.00 to $47.00 and gave the stock an “equal weight” rating in a report on Thursday, January 25th. Finally, StockNews.com started coverage on shares of Catalent in a report on Saturday. They issued a “sell” rating for the company. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $52.46.

Catalent Stock Up 0.2 %

Shares of Catalent stock opened at $55.92 on Friday. The company has a debt-to-equity ratio of 1.34, a current ratio of 2.48 and a quick ratio of 1.73. The company has a 50-day moving average of $56.73 and a 200 day moving average of $48.58. The firm has a market cap of $10.12 billion, a price-to-earnings ratio of -8.22, a PEG ratio of 6.04 and a beta of 1.20. Catalent, Inc. has a 1 year low of $31.45 and a 1 year high of $60.20.

Catalent (NYSE:CTLT) last issued its quarterly earnings results on Friday, February 9th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.22). Catalent had a negative return on equity of 2.43% and a negative net margin of 29.91%. The business had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.01 billion. During the same quarter in the previous year, the business earned $0.62 earnings per share. The firm’s revenue was down 10.2% compared to the same quarter last year. As a group, sell-side analysts anticipate that Catalent, Inc. will post 0.28 earnings per share for the current fiscal year.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.